From: Hypoxic exosomes orchestrate tumorigenesis: molecular mechanisms and therapeutic implications
Cancer | Breast | Ovarian | Pancreas | Myeloma | Gliablastoma | Prostate | Colorectal |
---|---|---|---|---|---|---|---|
Cell line | MCF7, SKBR3, and MDA-MB 231/ 4T1 | SKOV3, HO-8910 | BxPC-3 and AsPC-1 | RPMI8226, KMS-11, and U266 | U87MG | LNCaP and PC3 cells LNCaP, 22Rv1, PC3, and PWR-1E | HT29 and HCT116 CRC patients |
Hypoxic condition | 1% O2 and 0.1% O2 | 1% O2 | 1% O2 | 1% O2 | 1% O2 | 1% O2 | 1% O2 |
Cargo (Increased) | miR-21–3p, miR-125b-5p, and miR-181d-5p [132] | miR-21 [133] | miR-135b [134] | HIF mRNA, LOX, TSP1, VEGF, disintegrin, MMP, and ADAMTS1 [68] MMPs, IL-8, PDGFs, caveolin 1, and lysyl oxidase [107] | CD63, CD81, HSP90, HSP70, and Annexin II [67] Triglycerides, omega-6 fatty acids, linoleic acid, arachidonic acid, palmitic acids, stearic acids, and linoleic acids [135] lactic acid [136] | Wnt4 [137] miR-210 [108] |